Literature DB >> 19620344

D27-pLpxL, an avirulent strain of Yersinia pestis, primes T cells that protect against pneumonic plague.

Frank M Szaba1, Lawrence W Kummer, Lindsey B Wilhelm, Jr-Shiuan Lin, Michelle A Parent, Sara W Montminy-Paquette, Egil Lien, Lawrence L Johnson, Stephen T Smiley.   

Abstract

Vaccinating with live, conditionally attenuated, pigmentation (Pgm)-deficient Yersinia pestis primes T cells that protect mice against pneumonic plague. However, Pgm-deficient strains are not considered safe for human use because they retain substantial virulence in animal models. Y. pestis strains engineered to express Escherichia coli LpxL are avirulent owing to constitutive production of lipopolysaccharide with increased Toll-like receptor 4-activating ability. We generated an LpxL-expressing Pgm-deficient strain (D27-pLpxL) and demonstrate here that this avirulent strain retains the capacity to prime protective T cells. Compared with unvaccinated controls, mice immunized intranasally with live D27-pLpxL exhibit a decreased bacterial burden and increased survival when challenged intranasally with virulent Y. pestis. T cells provide a substantial degree of this protection, as vaccine efficacy is maintained in B-cell-deficient muMT mice unless those animals are depleted of CD4 and CD8 T cells at the time of challenge. Upon challenge with Y. pestis, pulmonary T-cell numbers decline in naive mice, whereas immunized mice show increased numbers of CD44(high) CD43(high) effector T cells and T cells primed to produce tumor necrosis factor alpha and gamma interferon; neutralizing these cytokines at the time of challenge abrogates protection. Immunization does not prevent dissemination of Y. pestis from the lung but limits bacterial growth and pathology in visceral tissue, apparently by facilitating formation of granuloma-like structures. This study describes a new model for studying T-cell-mediated protection against pneumonic plague and demonstrates the capacity for live, highly attenuated, Y. pestis vaccine strains to prime protective memory T-cell responses safely.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19620344      PMCID: PMC2747924          DOI: 10.1128/IAI.00273-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

Review 1.  Yersinia pestis (plague) vaccines.

Authors:  Richard W Titball; E Diane Williamson
Journal:  Expert Opin Biol Ther       Date:  2004-06       Impact factor: 4.388

2.  Defining the genome content of live plague vaccines by use of whole-genome DNA microarray.

Authors:  Dongsheng Zhou; Yanping Han; Erhei Dai; Yajun Song; Decui Pei; Junhui Zhai; Zongmin Du; Jin Wang; Zhaobiao Guo; Ruifu Yang
Journal:  Vaccine       Date:  2004-09-03       Impact factor: 3.641

Review 3.  Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

Authors:  T V Inglesby; D T Dennis; D A Henderson; J G Bartlett; M S Ascher; E Eitzen; A D Fine; A M Friedlander; J Hauer; J F Koerner; M Layton; J McDade; M T Osterholm; T O'Toole; G Parker; T M Perl; P K Russell; M Schoch-Spana; K Tonat
Journal:  JAMA       Date:  2000-05-03       Impact factor: 56.272

4.  Determination of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague.

Authors:  S Welkos; M L M Pitt; M Martinez; A Friedlander; P Vogel; R Tammariello
Journal:  Vaccine       Date:  2002-05-22       Impact factor: 3.641

5.  Live, attenuated Yersinia pestis vaccine: virulent in nonhuman primates, harmless to guinea pigs.

Authors:  K F Meyer; G Smith; L Foster; M Brookman; M Sung
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

6.  Stat 4 but not Stat 6 mediated immune mechanisms are essential in protection against plague.

Authors:  Stephen J Elvin; E Diane Williamson
Journal:  Microb Pathog       Date:  2004-10       Impact factor: 3.738

7.  Effectiveness of live or killed plague vaccines in man.

Authors:  K F Meyer
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

Review 8.  Immune defense against pneumonic plague.

Authors:  Stephen T Smiley
Journal:  Immunol Rev       Date:  2008-10       Impact factor: 12.988

9.  Generation of Yersinia pestis attenuated strains by signature-tagged mutagenesis in search of novel vaccine candidates.

Authors:  Yehuda Flashner; Emanuelle Mamroud; Avital Tidhar; Raphael Ber; Moshe Aftalion; David Gur; Shirley Lazar; Anat Zvi; Tamar Bino; Naomi Ariel; Baruch Velan; Avigdor Shafferman; Sara Cohen
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

10.  Protection from respiratory virus infections can be mediated by antigen-specific CD4(+) T cells that persist in the lungs.

Authors:  R J Hogan; W Zhong; E J Usherwood; T Cookenham; A D Roberts; D L Woodland
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

View more
  23 in total

1.  A protective epitope in type III effector YopE is a major CD8 T cell antigen during primary infection with Yersinia pseudotuberculosis.

Authors:  Yue Zhang; Patricio Mena; Galina Romanov; Jr-Shiuan Lin; Stephen T Smiley; James B Bliska
Journal:  Infect Immun       Date:  2011-11-07       Impact factor: 3.441

2.  Yersinia pestis Pla Protein Thwarts T Cell Defense against Plague.

Authors:  Stephen T Smiley; Frank M Szaba; Lawrence W Kummer; Debra K Duso; Jr-Shiuan Lin
Journal:  Infect Immun       Date:  2019-04-23       Impact factor: 3.441

3.  Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.

Authors:  Danielle A Wagner; Sean M Kelly; Andrew C Petersen; Nathan Peroutka-Bigus; Ross J Darling; Bryan H Bellaire; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2019-10-11       Impact factor: 8.947

4.  Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague.

Authors:  Devender Kumar; Girish Kirimanjeswara; Dennis W Metzger
Journal:  Clin Vaccine Immunol       Date:  2011-08-31

5.  Yersinia pestis YopE contains a dominant CD8 T cell epitope that confers protection in a mouse model of pneumonic plague.

Authors:  Jr-Shiuan Lin; Frank M Szaba; Lawrence W Kummer; Brett A Chromy; Stephen T Smiley
Journal:  J Immunol       Date:  2011-06-08       Impact factor: 5.422

6.  Deletion of the Braun lipoprotein-encoding gene and altering the function of lipopolysaccharide attenuate the plague bacterium.

Authors:  Jian Sha; Michelle L Kirtley; Christina J van Lier; Shaofei Wang; Tatiana E Erova; Elena V Kozlova; Anthony Cao; Yingzi Cong; Eric C Fitts; Jason A Rosenzweig; Ashok K Chopra
Journal:  Infect Immun       Date:  2012-12-28       Impact factor: 3.441

7.  IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection.

Authors:  Jr-Shiuan Lin; Lawrence W Kummer; Frank M Szaba; Stephen T Smiley
Journal:  J Immunol       Date:  2010-12-20       Impact factor: 5.422

8.  Intranasal prophylaxis with CpG oligodeoxynucleotide can protect against Yersinia pestis infection.

Authors:  Anthony J Hickey; Jr-Shiuan Lin; Lawrence W Kummer; Frank M Szaba; Debra K Duso; Michael Tighe; Michelle A Parent; Stephen T Smiley
Journal:  Infect Immun       Date:  2013-04-01       Impact factor: 3.441

9.  Fibrin facilitates both innate and T cell-mediated defense against Yersinia pestis.

Authors:  Deyan Luo; Jr-Shiuan Lin; Michelle A Parent; Isis Mullarky-Kanevsky; Frank M Szaba; Lawrence W Kummer; Debra K Duso; Michael Tighe; Jim Hill; Andras Gruber; Nigel Mackman; David Gailani; Stephen T Smiley
Journal:  J Immunol       Date:  2013-03-13       Impact factor: 5.422

10.  Pathogenicity of Yersinia pestis synthesis of 1-dephosphorylated lipid A.

Authors:  Wei Sun; David A Six; C Michael Reynolds; Hak Suk Chung; Christian R H Raetz; Roy Curtiss
Journal:  Infect Immun       Date:  2013-01-28       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.